TRAC, Canada and MedGenome announce a Cancer Immunotherapy solution – ETHealthworld.com
ETHealthworld.com |
TRAC, Canada and MedGenome announce a Cancer Immunotherapy solution
ETHealthworld.com July 20, 2017, Mumbai: Toronto Recombinant Antibody Centre (TRAC) from the University of Toronto, Canada agreed to license MedGenome’s patented cancer immunotherapy solution OncoPept to develop biomarkers for their drug candidates against … |
|
Researchers Design, Construct Genome-Wide Sequence-Verified Arrayed CRISPR Library
GenomeWeb But while similar approaches have been applied for selecting Cas9 sgRNAs for use with CRISPR, they added, Cas9-induced double-strand breaks (DSBs) leave a “genomic scar whose characteristics determine the phenotypic consequences of targeting a locus … |
UPI.com |
Number of T-cells predicts response to immunotherapy in melanoma
UPI.com “Combination immunotherapy is super-expensive and very toxic,” Dr. Adil Daud, director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center, said in a press release. “You’re putting patients at a lot of extra risk … Immune-cell numbers predict response to combination immunotherapy in melanomaMedical Xpress |
|
CRISPR/Cas9 May Aid Cancer Immunotherapy by Identifying Checkpoint Escapes
Genetic Engineering & Biotechnology News (blog) These scientists report that they have used CRISPR-Cas9 genome-editing technology to test the function of thousands of tumor genes in mice. Essentially, the scientists systematically screened for drug targets that could potentially enhance the … |
|
CRISPR-Cas9 May Aid Cancer Immunotherapy by Identifying Checkpoint Escapes
Genetic Engineering & Biotechnology News (press release) These scientists report that they have used CRISPR-Cas9 genome-editing technology to test the function of thousands of tumor genes in mice. Essentially, the scientists systematically screened for drug targets that could potentially enhance the … |